{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"UroGen Pharma Ltd."},"Symbol":{"label":"Symbol","value":"URGN"},"Address":{"label":"Address","value":"400 ALEXANDER PARK 4TH FLOOR, PRINCETON, New Jersey, 08540, United States"},"Phone":{"label":"Phone","value":"+1 646 768-9780"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Middle East"},"CompanyDescription":{"label":"Company Description","value":"UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy."},"CompanyUrl":{"label":"Company Url","value":"https://www.urogen.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Elizabeth Barrett","title":"President, Chief Executive Officer & Director"},{"name":"Marina Konorty","title":"Executive Vice President-Research & Development"},{"name":"Mark P. Schoenberg","title":"Chief Medical Officer"},{"name":"Moran Mieron","title":"Director-Research & Pre-Clinical Affairs"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}